Literature DB >> 22544206

Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria.

Richard Ugbena1, John Aberle-Grasse, Karidia Diallo, Orji Bassey, Tapdiyel Jelpe, Erin Rottinghaus, Aderemi Azeez, Raphael Akpan, Mukhtar Muhammad, Vedapuri Shanmugam, Satvinder Singh, Chunfu Yang.   

Abstract

This report describes a pilot study, conducted in Nigeria, of the World Health Organization protocol for monitoring human immunodeficiency virus (HIV) drug resistance (HIVDR) and associated program factors among patients receiving first-line antiretroviral therapy (ART). In 2008, 283 HIV-infected patients starting ART were consecutively enrolled at 2 ART clinics in Abuja. Twelve months after ART initiation, 62% were alive and on first-line ART, 3% had died, 1% had transferred out of the program, and 34% were lost to follow-up. Among patients on first-line ART at 12 months, 90% had viral suppression. However, in view of the high loss to follow-up rate (34%), strategies for patient retention and tracking are critical to minimize possible HIVDR and optimize treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544206     DOI: 10.1093/cid/cir1064

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

Review 2.  Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Authors:  Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

3.  Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.

Authors:  Karidia Diallo; Du-Ping Zheng; Erin K Rottinghaus; Orji Bassey; Chunfu Yang
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-05       Impact factor: 2.205

4.  The relationship between cognitive change and physical health and behavioural outcomes in a Ugandan cohort of adults living with HIV - a longitudinal study.

Authors:  G Spies; C A Denckla; S Mall; J Levin; S Seedat; N Nakasujja; E Kinyanda
Journal:  AIDS Care       Date:  2018-11-13

5.  Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Vincent Yapo; Thomas-d'Aquin Toni; Albert Minga; Martial Guillaume Kouakou; Eric Ouattara; Christine Rouzioux; Christine Danel; Serge P Eholie; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

6.  Individual and Network Factors Associated With HIV Care Continuum Outcomes Among Nigerian MSM Accessing Health Care Services.

Authors:  Habib O Ramadhani; Nicaise Ndembi; Rebecca G Nowak; Uchenna Ononaku; Jerry Gwamna; Ifeanyi Orazulike; Sylvia Adebajo; Trevor A Crowell; Hongjie Liu; Stefan D Baral; Julie Ake; Man E Charurat
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

7.  High Levels of HIV-1 Drug Resistance in Children Who Acquired HIV Infection Through Mother to Child Transmission in the Era of Option B+, Haiti, 2013 to 2014.

Authors:  Frantz Jean Louis; Nathanael Segaren; Olbeg Desinor; R Suzanne Beard; Reginald Jean-Louis; Joy Chang; Sylvie Boisson; Erin N Hulland; Nick Wagar; Joshua DeVos; Kesner François; Josiane Buteau; Jacques Boncy; Barbara J Marston; Jean Wysler Domerçant; Chunfu Yang; Macarthur Charles
Journal:  Pediatr Infect Dis J       Date:  2019-05       Impact factor: 2.129

8.  Risk factors for delayed initiation of combination antiretroviral therapy in rural north central Nigeria.

Authors:  Muktar H Aliyu; Meridith Blevins; Deidra D Parrish; Karen M Megazzini; Usman I Gebi; Mukhtar Y Muhammad; Mukhtar L Ahmed; Adiba Hassan; Bryan E Shepherd; Sten H Vermund; C William Wester
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

9.  Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria.

Authors:  Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

10.  NRTI backbone in HIV treatment: will it remain relevant?

Authors:  Randall Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.